• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

6.790 +0.070 (+1.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 373,860
Open 6.780
Bid (Size) 6.720 (100)
Ask (Size) 6.990 (200)
Prev. Close 6.720
Today's Range 6.521 - 7.020
52wk Range 6.610 - 50.40
Shares Outstanding 58,102,949
Dividend Yield 212.37%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
June 07, 2026
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗
June 02, 2026
RadNet runs a large outpatient imaging network and is building DeepHealth, its AI radiology platform. The upside is clearer if advanced imaging growth and digital health expansion can develop without... 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance

Performance

YTD
-57.6%
-57.6%
1 Month
-32.0%
-32.0%
3 Month
-44.8%
-44.8%
6 Month
-74.6%
-74.6%
1 Year
-78.3%
-78.3%

More News

Read More
News headline image
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗
May 27, 2026
Via The Motley Fool
Topics Regulatory Compliance
LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗
May 11, 2026
Via Chartmill
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗
March 24, 2026
Via Chartmill
News headline image
LENZ Therapeutics to Participate in Upcoming Investor Conferences
May 26, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Q1 Earnings Call Highlights ↗
May 11, 2026
Via MarketBeat
Topics Earnings
News headline image
Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗
May 11, 2026
Via The Motley Fool
Topics Earnings
News headline image
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 11, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
April 20, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗
March 27, 2026
Via The Motley Fool
News headline image
Why Lenz Therapeutics Stock Crashed Today ↗
March 24, 2026
Via The Motley Fool
News headline image
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 24, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗
March 23, 2026
Via Benzinga
News headline image
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
March 17, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
March 10, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
February 23, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
January 20, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
January 14, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
January 13, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
January 07, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
January 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
January 05, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
December 30, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
December 01, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?
Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?
LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?
The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market
What is the current price of LENZ Therapeutics, Inc. - Common Stock?
The current price of LENZ Therapeutics, Inc. - Common Stock is 6.790
When was LENZ Therapeutics, Inc. - Common Stock last traded?
The last trade of LENZ Therapeutics, Inc. - Common Stock was at 06/09/26 04:00 PM ET
What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?
The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 394.52M
How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?
LENZ Therapeutics, Inc. - Common Stock has 395M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap